Close Menu

NEW YORK – Agios said on Friday that it sold its royalty rights on worldwide net sales of enasidenib (Bristol Myers-Squibb's Idhifa), as well as its rights to receive up to $55 million in outstanding regulatory milestone payments from BMS, to Royalty Pharma for $255 million.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.